Announcement • Apr 30
Livzon Pharmaceutical Group Inc. (SZSE:000513) acquired 67.88% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6 trillion. Livzon Pharmaceutical Group Inc. (SZSE:000513) signed Framework Agreement to acquire 77.94% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6.9 trillion on May 22, 2025. A cash consideration of VND 5.73 trillion will be paid by Livzon Pharmaceutical Group Inc. As part of consideration, VND 5.73 trillion is paid towards common equity of Imexpharm Corporation. The Acquisition will be funded by the Group’s internal resources. The Acquisition will lay a solid foundation for the Group’s further expansion into overseas markets, supporting its long-term strategy of internationalization and sustainable development in the pharmaceutical sector. On December 29, 2025, the parties signed Amendment Agreement to Framework Agreement agreeing to increase the maximum number of shares to be acquired through this proposed public tender offer to 120,059,970 shares, 77.94% stake, in accordance with Imexpharm Corporation’s foreign ownership cap requirements, and the Company will pay a maximum of VND 6,891,442,278,000. As of March 6, 2026 Livzon Pharmaceutical Group has officially received approval from the State Securities Commission of Vietnam. This allows them to proceed with a voluntary public tender offer for IMP shares.
The transaction is subject to approval by merger control clearance, Permissible Foreign Ownership Limit, Absence of Material Adverse Change and other Customary Conditions. The number of shares intended to be sold by the Target Company’s shareholders does not reach the minimum threshold of 99,839,990 shares, representing 64.81% of the Target Company’s charter capital. The expected completion of the transaction is the date falling nine (9) months from the date of the Agreement. The transaction has been approved by the board of directors of Livzon Pharmaceutical Group Inc. Ernst & Young Vietnam Limited acted as due diligence provider to SK Investment Vina III Pte Ltd.
Livzon Pharmaceutical Group Inc. (SZSE:000513) completed the acquisition of 67.88% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6 trillion on April 29, 2026. Shareholders of Livzon Pharmaceutical Group Inc. have reached the minimum threshold of 99,839,990 shares, representing 64.81% of Imexpharm Corporation. Reported Earnings • Mar 28
Full year 2025 earnings: EPS in line with expectations, revenues disappoint Full year 2025 results: EPS: ₫1,976 (up from ₫1,791 in FY 2024). Revenue: ₫2.44t (up 11% from FY 2024). Net income: ₫304.4b (up 10% from FY 2024). Profit margin: 13% (in line with FY 2024). Revenue missed analyst estimates by 6.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 9.8% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Feb 09
Imexpharm Corporation, Annual General Meeting, Apr 22, 2026 Imexpharm Corporation, Annual General Meeting, Apr 22, 2026. 